Oncotarget

Research Papers:

Overwhelming rapid metabolic and structural response to apatinib in radioiodine refractory differentiated thyroid cancer

Yansong Lin _, Chen Wang, Wen Gao, Ruixue Cui and Jun Liang

PDF  |  HTML  |  How to cite  |  Order a Reprint

Oncotarget. 2017; 8:42252-42261. https://doi.org/10.18632/oncotarget.15036

Metrics: PDF 2230 views  |   HTML 2406 views  |   ?  


Abstract

Yansong Lin1,*, Chen Wang1,*, Wen Gao2, Ruixue Cui1 and Jun Liang3

1Department of Nuclear Medicine, Peking Union Medical College Hospital, Beijing 100730, China

2Department of Oncology, The Affiliated Hospital of Qingdao University, Qingdao 266555, China

3Department of Oncology, Peking University International Hospital, Beijing 102206, China

*These authors have contributed equally to this work

Correspondence to:

Yansong Lin, email: linys@pumch.cn

Jun Liang, email: liangjun1959@aliyun.com

Keywords: apatinib, radioiodine refractory differentiated thyroid cancer, thyroglobulin, maximum standard uptake value, safety

Received: September 26, 2016    Accepted: January 08, 2017    Published: February 02, 2017

ABSTRACT

Currently, patients with radioiodine refractory differentiated thyroid cancer (RAIR-DTC) have limited treatment options. In this study, we aimed to assess the short-term efficacy and safety of apatinib in RAIR-DTC. Ten adult patients were prospectively enrolled to receive oral apatinib (750 mg q.d). The primary endpoints were change in serum thyroglobulin (Tg) concentration, disease control rate (DCR) and objective response rate (ORR) based on RECIST 1.1 criteria. The secondary endpoints included change in glucose metabolism, evaluated by maximum standard uptake value (SUVmax), and safety. As early as 2 weeks after apatinib treatment, the serum Tg concentration decreased by 21.0% in 8 patients available for detection without interference, and a further sharp decline by 81.4% compared with the baseline level occurred at 8 weeks post-treatment. The DCR and ORR were 100% (10/10) and 90% (9/10), respectively. The sum of tumor diameter shrank to 22.8±8.1 mm from 38.8±15.7 mm (P=0.001). Moreover, a significant decrease in SUVmax was observed from 6.53±5.14 to 2.56±1.67 and 2.45±1.48 at 4-week and 8-week time-points after treatment (P=0.032 and 0.020), respectively. The common grade 3 adverse events (AEs) included hand-foot-skin reaction (50%), hypertension (30%), and hypocalcemia (20%). No severe AE related to apatinib was observed during treatment. Hence, apatinib seems to be a promising therapeutic option for RAIR-DTC patients. Apart from RECIST 1.1 criteria, the biochemical marker (Tg) and glucose metabolism index (SUVmax) could be adopted in assessing the early response to TKI in RAIR-DTC.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 15036